-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
9 views
Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company's pipeline includes promising programs for SYNGAP-1, Rett syndrome, and ADOA, with industry validation via impressive new partnerships with Biogen and Acadia. Financially, Stoke is buoyed by its new milestone-rich deals, but as a ticker it faces high short interest and high volatility.
